Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) announced that on December 18, 2025, Fosun Pharmaceutical Industry, a holding subsidiary of the company, signed a “Cooperation and Choice Agreement” with its partner Clavis Bio. According to the agreement, within the agreed cooperation period, Fosun Pharmaceutical Industry and Clavis Bio will jointly select targets (based on Clavis Bio nominations) and promote pre-clinical development of selected target compounds (i.e. cooperative projects). Clavis Bio has the right to choose an exclusive license for development, production and commercialization of such cooperative projects on a global scale other than within China, Hong Kong, China, and Macau; regardless of whether the partner exercises these options, the Group enjoys the right to exclusively develop, produce and commercialize such cooperative projects within China, Hong Kong, China, and Macau.

Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) announced that on December 18, 2025, Fosun Pharmaceutical Industry, a holding subsidiary of the company, signed a “Cooperation and Choice Agreement” with its partner Clavis Bio. According to the agreement, within the agreed cooperation period, Fosun Pharmaceutical Industry and Clavis Bio will jointly select targets (based on Clavis Bio nominations) and promote pre-clinical development of selected target compounds (i.e. cooperative projects). Clavis Bio has the right to choose an exclusive license for development, production and commercialization of such cooperative projects on a global scale other than within China, Hong Kong, China, and Macau; regardless of whether the partner exercises these options, the Group enjoys the right to exclusively develop, produce and commercialize such cooperative projects within China, Hong Kong, China, and Macau.